Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Transgene
  6. News
  7. Summary
    TNG   FR0005175080

TRANSGENE

(TNG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Transgene and BioInvent to Present Preclinical Data on BT-001 Oncolytic Virus at SITC 2021

10/01/2021 | 09:00am EST

Transgene and BioInvent International AB announced that they will present additional preclinical data on their novel dual mechanism-of-action oncolytic vaccinia virus BT-001 at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC2021) in November 2021. SITC2021 will take place on November 10–14, 2021, at the Walter E. Washington Convention Center in Washington, D.C. and virtually. The poster will be presented on November 13, with the title “Vectorized Treg-depleting aCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject “cold” tumors”. Authors: Monika Semmrich, Jean-Baptiste Marchand, Matilda Rehn, Laetitia Fend, Christelle Remy, Petra Holmkvist, Nathalie Silvestre, Carolin Svensson, Patricia Kleinpeter, Jules Deforges, Fred Junghus, Linda Mårtensson, Johann Foloppe, Ingrid Teige, Eric Quéméneur and Björn Frendéus. BT-001 is an oncolytic virus generated using Transgene’s Invir.IO platform and its patented large-capacity VVcopTK-RR- oncolytic virus, which has been engineered to encode both a Treg-depleting human recombinant anti-CTLA-4 antibody generated by BioInvent’s proprietary n-CoDeR/F.I.R.S.T platforms, and the human GM-CSF cytokine. By selectively targeting the tumor microenvironment, BT-001 is expected to elicit a much stronger and more effective antitumoral response. As a consequence, by reducing systemic exposure, the safety and tolerability profile of the anti-CTLA-4 antibody is expected to be greatly improved. BT-001 is being co-developed as part of a 50/50 collaboration between BioInvent and Transgene. Recruitment in the ongoing Phase I/IIa clinical study of BT-001 (NCT04725331) in Europe and the U.S. is progressing well. The trial evaluates BT-001 as a single agent and in combination with pembrolizumab for the treatment of solid tumors. Initial Phase I data are expected in the first half of 2022.


© S&P Capital IQ 2021
All news about TRANSGENE
11/22Transgene and NEC Corporation Announce Positive Preliminary Data from Phase I Studies o..
CI
11/09Transgene and BioInvent Present Preclinical Data Highlighting the Robust Anti-Tumoral A..
CI
10/01BIOINVENT INTERNATIONAL : and Transgene to present preclinical data on BT-001 oncolytic vi..
AQ
10/01Transgene and BioInvent to Present Preclinical Data on BT-001 Oncolytic Virus at SITC 2..
CI
09/23Certain Ordinary Shares of Transgene SA are subject to a Lock-Up Agreement Ending on 23..
CI
09/16TRANSGENE : Gastrointestinal Cancer Drug Study Confirms Potential of Cancer-Killing Virus
MT
09/16Transgene Presents Data from Phase I Clinical Trial Confirming the Potential of the Onc..
CI
09/13GLOBAL MARKETS LIVE : Valneva, Walt Disney, ViacomCBS, General Motors, Amazon...
09/02GLOBAL MARKETS LIVE : Ford, Walmart, Apple, Volkswagen, Tesla...
09/01Transgene Participates in New Cancer Research Consortium
CI
More news
Financials
Sales 2021 10,2 M 11,5 M 11,5 M
Net income 2021 -29,8 M -33,6 M -33,6 M
Net cash 2021 3,35 M 3,78 M 3,78 M
P/E ratio 2021 -7,85x
Yield 2021 -
Capitalization 257 M 290 M 290 M
EV / Sales 2021 25,0x
EV / Sales 2022 33,9x
Nbr of Employees 133
Free-Float 44,0%
Chart TRANSGENE
Duration : Period :
Transgene Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TRANSGENE
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 2,63 €
Average target price 3,80 €
Spread / Average Target 44,5%
EPS Revisions
Managers and Directors
Hedi Ben Brahim Chairman & Chief Executive Officer
Hedi Ben Brahim Chairman & Chief Executive Officer
Jean-Philippe Del Chief Financial Officer
Eric Quéméneur Chief Scientific Officer & Executive VP
Hemanshu Shah VP-Medical Affairs & International Development
Sector and Competitors
1st jan.Capi. (M$)
TRANSGENE58.98%290
GILEAD SCIENCES, INC.19.40%87 255
BIONTECH SE310.30%83 098
REGENERON PHARMACEUTICALS31.23%66 409
WUXI APPTEC CO., LTD.26.31%65 758
VERTEX PHARMACEUTICALS-13.76%51 819